 SAN DIEGO--BUSINESS WIRE--Biocept, Inc. Nasdaq: BIOC, a leading provider of molecular diagnostic assays, products and services, will present data showing that its Target SelectorTM molecular assay kit detects mutations in up to 50 of tissue biopsy specimens, from patients diagnosed with non-small cell lung cancer, that were deemed quantity not sufficient QNS. The study will be presented at the Molecular Med Tri-Con Virtual Conference, Feb. 16-18, 2021. Molecular testing of biopsy specimen 